Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BLINKB-ALL: BLinatumomab and iNKT in Relapsed B-Cell ALL

NCT07869368 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT07869368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07869368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BLINKB-ALL: BLinatumomab and iNKT in Relapsed B-Cell ALL
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
February 28, 2030
Enrollment
13 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

all (acute b-lymphoblastic leukemia), b-cell all, cd19-positive b-cell acute, philadelphia chromosome-negative lymphoblastic leukemia